BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36217758)

  • 21. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
    Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
    Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
    Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.
    Jin X; Fang R; Fan P; Zeng L; Zhang B; Lu X; Liu T
    J Exp Clin Cancer Res; 2019 Nov; 38(1):463. PubMed ID: 31718704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
    Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
    Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
    Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
    J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing novel long non-coding RNA FKBP9P1 represses malignant progression and inhibits PI3K/AKT signaling of head and neck squamous cell carcinoma in vitro.
    Yang YF; Feng L; Shi Q; Ma HZ; He SZ; Hou LZ; Wang R; Fang JG
    Chin Med J (Engl); 2020 Sep; 133(17):2037-2043. PubMed ID: 32769488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Silencing of long non-coding RNA LINC00520 promotes radiosensitivity of head and neck squamous cell carcinoma cells.
    Li J; Liu X; Nan S; Xu C
    Free Radic Res; 2020 Apr; 54(4):254-270. PubMed ID: 32462956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line.
    Miari R; Azzam N; Bar-Shalom R; Fares F
    PLoS One; 2021; 16(9):e0253756. PubMed ID: 34534222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma.
    Tong T; Qin X; Jiang Y; Guo H; Wang X; Li Y; Xie F; Lu H; Zhai P; Ma H; Zhang J
    BMC Med; 2022 Jul; 20(1):231. PubMed ID: 35773668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
    Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
    Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
    Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
    Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
    Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
    Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
    Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma.
    Lee SH; Do SI; Lee HJ; Kang HJ; Koo BS; Lim YC
    Lab Invest; 2016 May; 96(5):508-16. PubMed ID: 26927514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.
    Cui L; Lu Y; Zheng J; Guo B; Zhao X
    J Exp Clin Cancer Res; 2023 Dec; 42(1):335. PubMed ID: 38057867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
    Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
    Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.